Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 10, 2008, Pages 1112-1118

  Bepler, Gerold ^a   Sommers, K Eric ^a   Cantor, Alan ^a   Li, Xueli ^a   Sharma, Anupama ^a   Williams, Charles ^a   Chiappori, Alberto ^a   Haura, Eric ^a   Antonia, Scott ^a   Tanvetyanon, Tawee ^a   Simon, George ^a   Obasaju, Coleman ^b   Robinson, Lary A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Gemcitabine; Non small cell lung cancer; Pemetrexed; Ribonucleotide reductase; Thymidylate synthase

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GEMCITABINE; MESSENGER RNA; MOLECULAR MARKER; PEMETREXED; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CELLULITIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; MULTIPLE CYCLE TREATMENT; ONCOGENE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHLEBITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RRM1 GENE; THORACOTOMY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TS GENE; TUMOR VOLUME; VIRUS PNEUMONIA; ADJUVANT THERAPY; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 58949097480     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181874936     Document Type: Article

References (19)

1. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
2. Winton TL, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
4. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
5. Scagliotti G. Preliminary results of Ch.E.S.T.: a phase III study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in clinical early stages non-small cell lung cancer. Proc Am Soc Clin Oncol 2005;23:626s.
6. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT/EORTC 08012 multicentre randomized trial and update of systemic review. Lancet 2007;369:1929-1937.
7. Pisters KM, Vallieres E, Bunn PA, et al. S9900: surgery alone or surgery plus induction paclitaxel/carboplatin chemotherapy in early stage non-small cell lung cancer. Proc Am Soc Clin Oncol 2007;25:389s.
8. Ramnath N, Sommers E, Robinson L, et al. Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Chest 2005;128:3467-3474.
9. Ma C, Nair S, Thomas S, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-5937.
10. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999;59:3671-3676.
11. Adjei AA. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. Semin Oncol 2002;29(Suppl 18):30-34.
12. Mey V, Giovanetti E, De Braud F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006; 95:289-297.
13. Dudek A, Larson T, McCleod M, et al. Phase 1/2 dose escalading study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3:394-399.
14. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:1878-1885.
15. Spearman C. The proof and measurement of association between two things. Am J Psychol 1904;15:72-101.
16. Bonferroni C. Teoria statistica delle classi e calcolo delle probabilita. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali de Firenze 1936;8:3-62.
17. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
18. Rosell R, Gomez-Codina J, Camps C, et al. Randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
19. Roth JA, Fosella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994;86:673-680.